IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0053733.html
   My bibliography  Save this article

Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib

Author

Listed:
  • Fernando Lopez-Rios
  • Barbara Angulo
  • Belen Gomez
  • Debbie Mair
  • Rebeca Martinez
  • Esther Conde
  • Felice Shieh
  • Jeffrey Vaks
  • Rachel Langland
  • H Jeffrey Lawrence
  • David Gonzalez de Castro

Abstract

Background: The cobas 4800 BRAF V600 Mutation Test is a CE-marked and FDA-approved in vitro diagnostic assay used to select patients with metastatic melanoma for treatment with the selective BRAF inhibitor vemurafenib. We describe the pre-approval validation of this test in two external laboratories. Methods: Melanoma specimens were tested for BRAF V600 mutations at two laboratories with the: cobas BRAF Mutation Test; ABI BRAF test; and bidirectional direct sequencing. Positive (PPA) and negative (NPA) percent agreements were determined between the cobas test and the other assays. Specimens with discordant results were tested with massively parallel pyrosequencing (454). DNA blends with 5% mutant alleles were tested to assess detection rates. Results: Invalid results were observed in 8/116 specimens (6·9%) with Sanger, 10/116 (8·6%) with ABI BRAF, and 0/232 (0%) with the cobas BRAF test. PPA was 97·7% for V600E mutation for the cobas BRAF test and Sanger, and NPA was 95·3%. For the cobas BRAF test and ABI BRAF, PPA was 71·9% and NPA 83·7%. For 16 cobas BRAF test-negative/ABI BRAF-positive specimens, 454 sequencing detected no codon 600 mutations in 12 and variant codon 600 mutations in four. For eight cobas BRAF test-positive/ABI BRAF-negative specimens, four were V600E and four V600K by 454 sequencing. Detection rates for 5% mutation blends were 100% for the cobas BRAF test, 33% for Sanger, and 21% for the ABI BRAF. Reproducibility of the cobas BRAF test was 111/116 (96%) between the two sites. Conclusions: It is feasible to evaluate potential companion diagnostic tests in external laboratories simultaneously to the pivotal clinical trial validation. The health authority approved assay had substantially better performance characteristics than the two other methods. The overall success of the cobas BRAF test is a proof of concept for future biomarker development.

Suggested Citation

  • Fernando Lopez-Rios & Barbara Angulo & Belen Gomez & Debbie Mair & Rebeca Martinez & Esther Conde & Felice Shieh & Jeffrey Vaks & Rachel Langland & H Jeffrey Lawrence & David Gonzalez de Castro, 2013. "Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib," PLOS ONE, Public Library of Science, vol. 8(1), pages 1-7, January.
    • Handle: RePEc:plo:pone00:0053733
    DOI: 10.1371/journal.pone.0053733
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0053733
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0053733&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0053733?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Marcel Margulies & Michael Egholm & William E. Altman & Said Attiya & Joel S. Bader & Lisa A. Bemben & Jan Berka & Michael S. Braverman & Yi-Ju Chen & Zhoutao Chen & Scott B. Dewell & Lei Du & Joseph , 2005. "Genome sequencing in microfabricated high-density picolitre reactors," Nature, Nature, vol. 437(7057), pages 376-380, September.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. David J H F Knapp & Rachel A McGovern & Art F Y Poon & Xiaoyin Zhong & Dennison Chan & Luke C Swenson & Winnie Dong & P Richard Harrigan, 2014. "“Deep” Sequencing Accuracy and Reproducibility Using Roche/454 Technology for Inferring Co-Receptor Usage in HIV-1," PLOS ONE, Public Library of Science, vol. 9(6), pages 1-10, June.
    2. Chongqing Wen & Liyou Wu & Yujia Qin & Joy D Van Nostrand & Daliang Ning & Bo Sun & Kai Xue & Feifei Liu & Ye Deng & Yuting Liang & Jizhong Zhou, 2017. "Evaluation of the reproducibility of amplicon sequencing with Illumina MiSeq platform," PLOS ONE, Public Library of Science, vol. 12(4), pages 1-20, April.
    3. Jiang Du & Robert D Bjornson & Zhengdong D Zhang & Yong Kong & Michael Snyder & Mark B Gerstein, 2009. "Integrating Sequencing Technologies in Personal Genomics: Optimal Low Cost Reconstruction of Structural Variants," PLOS Computational Biology, Public Library of Science, vol. 5(7), pages 1-15, July.
    4. Peri, Alessandro, 2020. "A hardware approach to value function iteration," Journal of Economic Dynamics and Control, Elsevier, vol. 114(C).
    5. Marvin Mundry & Erich Bornberg-Bauer & Michael Sammeth & Philine G D Feulner, 2012. "Evaluating Characteristics of De Novo Assembly Software on 454 Transcriptome Data: A Simulation Approach," PLOS ONE, Public Library of Science, vol. 7(2), pages 1-10, February.
    6. Ben Jia & Liming Xuan & Kaiye Cai & Zhiqiang Hu & Liangxiao Ma & Chaochun Wei, 2013. "NeSSM: A Next-Generation Sequencing Simulator for Metagenomics," PLOS ONE, Public Library of Science, vol. 8(10), pages 1-10, October.
    7. Tsunglin Liu & Cheng-Hung Tsai & Wen-Bin Lee & Jung-Hsien Chiang, 2013. "Optimizing Information in Next-Generation-Sequencing (NGS) Reads for Improving De Novo Genome Assembly," PLOS ONE, Public Library of Science, vol. 8(7), pages 1-16, July.
    8. Yen-Chun Chen & Tsunglin Liu & Chun-Hui Yu & Tzen-Yuh Chiang & Chi-Chuan Hwang, 2013. "Effects of GC Bias in Next-Generation-Sequencing Data on De Novo Genome Assembly," PLOS ONE, Public Library of Science, vol. 8(4), pages 1-20, April.
    9. Cirella, Giuseppe T. & Zerbe, Stefan, 2014. "Sustainable Water Management and Wetland Restoration Strategies in Northern China," MPRA Paper 120233, University Library of Munich, Germany.
    10. Yu-Tsueng Liu & Dennis A Carson, 2007. "A Novel Approach for Determining Cancer Genomic Breakpoints in the Presence of Normal DNA," PLOS ONE, Public Library of Science, vol. 2(4), pages 1-8, April.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0053733. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.